China Analyst Identifies 10 Pharma Stocks with Highest Growth Potential

China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.

Read more »

For Vax Providers, Flu Season Off to a Running Start

It’s flu season again, and more than 690,000 people in the U.S. have already been vaccinated, reports healthcare analytics service SDI.

Read more »

FDA to Collaborate with Pharma Companies on New TB Initiative

A number of pharmaceutical companies will collaborate with FDA scientists to test new TB combination therapies and identify promising candidates.

Read more »

[Video Profile] Inovio Biomedical Corporation

Solid tumors represent 85 percent of all cancers, creating a huge clinical need for localized, site-specific cancer treatment. Inovio Medical Corporation of San Diego is developing DNA-based vaccines that harness the body’s immune system to prevent and treat chronic diseases such as cancer and HIV.

Read more »

Two Studies Show Potential for Treating Drug-Resistant TB

Tuberculosis, or TB, is one of the world’s most widespread lethal diseases, killing someone every 20 seconds. An estimated one-third of the world’s population is infected with tuberculosis. Current medications for TB must be taken for six months, but many patients stop before they’ve completed the full course, which has caused drug-resistant strains of TB to develop in recent years. However, two new studies are showing promise in treating this highly infectious disease.

According to Science Daily, the Albert Einstein College of Medicine at Yeshiva University found that a combination of two FDA-approved antibiotics showed potential for treating drug-resistant TB. One of the drugs, clavulanate, inhibits a bacterial enzyme that normally protects TB bacteria from the other antibiotic (meropenem). Clinical trials of the combined treatment are scheduled to take place later this year in South Africa and South Korea.

Read more »